



MARKET RELEASE

19 January 2009

Neuren Pharmaceuticals Limited

TRADING HALT

The securities of Neuren Pharmaceuticals Limited (the "Company") will be placed in pre-open at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in pre-open until the earlier of the commencement of normal trading on Wednesday, 21 January 2009 or when the announcement is released to the market.

Security Code: NEU

Lux Wigneswaran
Adviser, Issuers (Sydney)



Neuren Pharmaceuticals Ltd
Level 2, 57 Wellington Street
Freemans Bay, Auckland, New Zealand
office: +64 9 529 3940
fax: +64 9 361 7981
enquiries@neurenpharma.com
www.neurenpharma.com

19 January 2009

Ms Emma Badhni
Senior Adviser, Issuers (Sydney)
Australian Stock Exchange Limited
Level 6, 20 Bridge Street
Sydney NSW 2000

By Email

Dear Ms Badhni

TRADING HALT REQUEST

The Directors of Neuren Pharmaceuticals Limited (ASX Code: NEU) hereby request a trading halt of the Company's securities.

The trading halt is requested pending an announcement to the market concerning the business strategy for the Company in light of the recent trial results for Glypromate®. The announcement will discuss the development plans for the Company's second lead candidate, NNZ-2566, and other compounds in the Company's portfolio, and is expected to be made on or before the opening of trading on Wednesday 21 January 2009.

The Company is not aware of any reason why the trading halt should not be granted.

Yours sincerely

A handwritten signature in black ink, appearing to read "Rob Turnbull".

Rob Turnbull
Chief Financial Officer